Our data show also that siRNA-mediated eIF4A3 depletion drives cell death even in a p53-independent manner, thereby further expanding the therapeutic potential of eIF4A3 inhibition in AML with mutant p53. The gene discussed is TP53; the disease is acute myeloid leukemia.